1. ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.
- Author
-
Carballo-Jane E, Chen Z, O'Neill E, Wang J, Burton C, Chang CH, Chen X, Eveland S, Frantz-Wattley B, Gagen K, Hubbard B, Ichetovkin M, Luell S, Meurer R, Song X, Strack A, Langella A, Cianetti S, Rech F, Capitò E, Bufali S, Veneziano M, Verdirame M, Bonelli F, Monteagudo E, Pessi A, Ingenito R, and Bianchi E
- Subjects
- Animals, High-Density Lipoproteins, Pre-beta drug effects, Humans, Lipoproteins, HDL metabolism, Mice, Molecular Mimicry, Peptide Fragments pharmacology, Structure-Activity Relationship, Triglycerides metabolism, Apolipoprotein A-I chemistry, High-Density Lipoproteins, Pre-beta biosynthesis, Lipoproteins, HDL drug effects, Peptide Fragments chemistry, Triglycerides biosynthesis
- Abstract
Reverse cholesterol transport promoted by HDL-apoA-I is an important mechanism of protection against atherosclerosis. We have previously identified apoA-I mimetic peptides by synthesizing analogs of the 22 amino acid apoA-I consensus sequence (apoA-I(cons)) containing non-natural aliphatic amino acids. Here we examined the effect of different aliphatic non-natural amino acids on the structure-activity relationship (SAR) of apoA-I mimetic peptides. These novel apoA-I mimetics, with long hydrocarbon chain (C(5-8)) amino acids incorporated in the amphipathic α helix of the apoA-I(cons), have the following properties: (i) they stimulate in vitro cholesterol efflux from macrophages via ABCA1; (ii) they associate with HDL and cause formation of pre-β HDL particles when incubated with human and mouse plasma; (iii) they associate with HDL and induce pre-β HDL formation in vivo, with a corresponding increase in ABCA1-dependent cholesterol efflux capacity ex vivo; (iv) at high dose they associate with VLDL and induce hypertriglyceridemia in mice. These results suggest our peptide design confers activities that are potentially anti-atherogenic. However a dosing regimen which maximizes their therapeutic properties while minimizing adverse effects needs to be established., (Copyright © 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF